JPRN-UMIN000029633已完成未知
The efficacy of indigo naturalis-containing suppository in patients with active ulcerative colitis. - The efficacy of indigo naturalis-containing suppository in patients with active ulcerative colitis.
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Patients who are clinically classified into severe or fulminant condition or have other conditions besides UC,such as infectious enteritis and so on. 2.Patients with symptomatic stenosis. 3.Patients who are planned to undergo surgery or patients who have experienced adverse effect or allergy of herbal medicines, and patients who have had herbal medicine which contains IN. 4.Patients with severe infection, severe heart disease,2.0 mg per dl or higher serum creatinine levels,2.0mg per dl or higher serum total bilirubin levels, 50IU per l or higher serum AST and ALT levels, malignant tumor or its previous history,and neuropsychiatric disorders. 5.Patients who have possibility of pregnancy, or patients in nursing, or patients who hope to get pregnant. 6.Patients who are decided to be inappropriate for other reason by attending doctors. 7.Exclusion criteria about concomitant drugs. Changing dose of oral 5 aminosalicylate(5ASA)within 2 weeks before registration.Use of suppository or enema of 5-ASA or steroid within 2 weeks before registration.Receiving Granulocyte Monocyte Apheresis within 2 weeks before registration.Starting immunomodulators (azathioprine and 6-mercaptopurine),and changing dose of them within 4 weeks before registration.Use of 20mg or more of oral prednisolone or equivalent corticosteroid (the route: intravenous, intra-arterial , or intramuscular administration) within 2 weeks before registration. As for patients who receive 20mg or less oral prednisolone (or equivalent corticosteroid), changing dose or administration of oral prednisolone within 2 weeks before registration.Use of adalimumab within 4 weeks before registration.Use of infliximab or vedolizumab within 8 weeks before registration.Use of ustekinumab or herbal medicines other than IN within 12 weeks before registration.Use of cyclosporine (oral or intravenous administration) or tacrolimus (except for eye drops) within 2 weeks before registration.
研究者
相似试验
招募中
3 期
IN for practical useulcertive colitisJPRN-jRCTs031190156Kanai Takanori100
已完成
不适用
Safety and efficacy of indigo naturalis for chronic enteropathy associated with SLCO2A1 and Cronkhite-Canada syndrome.chronic enteropathy associated with SLCO2A1 and Cronkhite-Canada syndromeJPRN-UMIN000025246Keio University Gastroenterology and Hepatology6
招募中
不适用
Investigation of the safety of Indigo naturalis for the patients with ulcerative colitisulcerative colitisJPRN-UMIN000017359Osaka University, Graduate School of Medicine, Department of Gastroenterology and Hepatology20
已完成
3 期
Study of the efficacy of Indigo Naturalis ointment in the treatment of Plaque – type Psoriasis and comparison between ointments made of two different Chinese and Iranian herbs and betamethasone ointmentPsoriasis.PsoriasisIRCT201512157265N5Mashhad University of Medical Sciences30
已完成
不适用
Investigation of clinical usefulness of natural indigo ointment for patients with chemotherapy-induced oral mucositisChemotherapy-induced oral mucositisJPRN-UMIN000024271Keio University19